Since the introduction of the first autoinjector device in 1980s, their numerous benefits, such as ease-of-use, reduced chances of dosing errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries, have been widely recognized among consumers and healthcare service providers. Autoinjectors are also considered to be potential life cycle management tool. Drugs nearing patent expiry can be developed for delivery using an autoinjector and retain market exclusivity as a combination product. Various initiatives are underway to make these devices even more patient-friendly; in fact, between January 2013 and December 2017, close to 3,800 patents have been published in this domain, indicating the rapid pace at which research is being carried out in this field.
The Market Landscape of Autoinjectors is Steadily Widening
Over 85 unique autoinjector devices and 75 drug-autoinjector combination products are currently available in the market
The Interest is Validated by a Large Number of Recently Filed Patents
As a result of the widening research interest, close to 3,800 patents have been filed recently; automated self-injection devices, with improved features, are gradually becoming mainstream
Healthy Competition Among Stakeholders is Fostering Technological Advances
Ongoing innovation has led to the development of robust technology platforms that have significantly strengthened the growing product landscape in this domain
The Development Focus is Spread Across a Variety of Target Therapeutic Areas
Several combination products are already approved for a diverse array of indications; majority of them are disposable in nature and designed for subcutaneous drug delivery
Our Proprietary Analysis Reveals Several Drugs that are Suited for Delivery via Autoinjectors
A detailed evaluation of both marketed / pipeline products highlights several drug candidates that are suited for delivery via autoinjectors
We Expect the Market to Steadily Evolve Over the Next Decade …
Overall, the autoinjectors market is poised to grow at a steady pace in the mid-long term; the opportunity is likely to be well-distributed across different regions of the world
… As Devices with New Features Get Commercialized for A Wider Pool of Indications
Rising incidence of chronic conditions is expected to drive future growth; devices offering subcutaneous drug delivery will continue to capture over 90% of the market’s share
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. Alternatively, you can place an Order by filling this Order Form.